ENTHERA-PHARMACEUTICALS
Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
The Series A was co-led by seed investor Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and incoming investor AbbVie, with further investment from the JDRF T1D Fund (the venture capital fund of JDRF) and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The €28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.
The Series A marks AbbVie’s first venture investment into an Italian company. Enthera was also the first European investment of the JDRF T1D fund, who previously invested in the Company during its €4 million seed extension funding round in 2018.
The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate. Ent001 is the only drug in development with the potential to restore the pancreatic beta cell compartment in type 1 diabetes as well as the original intestine structure in inflammatory bowel disease, in order to re-establish organ function. The funds will also be used to further develop Enthera’s pipeline.
Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: “Having renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund choosing to support us on our journey is great validation of our company strategy and scientific method, and gives credit to the innovative science that is currently underway in Italy.
“We have a revolutionary approach that offers a new perspective for intractable diseases such as type 1 diabetes and inflammatory bowel disease, and the funds raised will enable us to accelerate our lead program Ent001 to clinical proof-of-concept. Through this and the development of our wider pipeline, we have the opportunity to bring real hope to patients in need and to provide effective and safe treatments.”
Graziano Seghezzi, Managing Partner of Sofinnova Partners, who co-seeded the company, stated:
“Enthera’s Series A financing is a fantastic milestone enabled by the leadership of Giovanni who, since his arrival in the company, has expanded its activities into novel therapeutic areas. This is also an opportunity for us to applaud BiovelocITA’s role in transforming the breakthrough science originating from Paolo Fiorina and his team into a full-fledged enterprise. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class science, experienced management, and dedicated financial capital.”
Margarita Chavez, Managing Director of AbbVie Ventures and new addition to the Enthera Board of Directors, added: “AbbVie Ventures’ investment in Enthera’s Series A demonstrates our confidence in the team and their unique approach to treating underserved autoimmune disorders. I look forward to working with Giovanni and rest of the team as we drive the Company and its innovation forward.”
Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio. The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund. A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.
ENDS
Notes to Editors
About Enthera
Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).
Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.
The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.
Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca D’Addio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Enthera’s discovery engine and assets are protected by a broad portfolio of patents.
For more information, visit https://www.entherapharmaceuticals.com/
Connect with us on LinkedIn .
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
About AbbVie Ventures
AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization.
For more information, please visit www.abbvie.com/ventures
For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter, Facebook , Instagram , YouTube and LinkedIn .
About the JDRF T1D Fund
The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance therapeutics, devices, diagnostics and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.
BiovelocITA
BiovelocITA S.r.l. is the first Italian accelerator dedicated to biotech. It was founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. Thanks to BiovelocITA, entrepreneurs, scientists and investors can work together to accelerate biotech projects with an international scope and reach the “proof of concept” that precedes the clinical phase. Set up to offer innovative solutions to the medical community and to patients, BiovelocITA supports the creation and development of innovative biotech companies in all therapeutic areas.
For more information, see: http://www.biovelocita.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo Holdings fejrer sin børsnotering på New York Stock Exchange23.1.2026 03:52:00 CET | Pressemeddelelse
BitGo Holdings, Inc. ("BitGo", "virksomheden", "vi"), en virksomhed inden for digital infrastruktur til aktiver, fejrer i dag sin lancering på New York Stock Exchange ("NYSE") som et børsnoteret selskab under tickersymbolet "BTGO". Medlemmer af BitGos ledelsesteam vil i dag kl. 09:30 ET ringe med åbningsklokken på NYSE. "I dag markerer et afgørende øjeblik for BitGo," udtaler Mike Belshe, administrerende direktør og medstifter af BitGo. "Vores indtræden på de offentlige markeder vil gøre det muligt for os yderligere at accelerere det finansielle systems overgang til en gennemsigtig og troværdig digital aktivøkonomi, samtidig med at vi fortsat kan levere enestående sikkerheds-, depot- og likviditetsløsninger til vores kunder. Vi er overbeviste om, at potentialet forude er stort, og at vi er unikt positioneret til at hjælpe institutioner med at gå fremtiden i møde." Belshe fortsætter: "Jeg er utroligt stolt af den virksomhed, vi har opbygget, og dybt taknemmelig for vores teams hårde arb
Tinaba with Banca Profilo Strengthens Its Global Positioning and Launches Digital Payments in the Chinese Mainland with Alipay+23.1.2026 02:41:00 CET | Press release
Through the “Pay Worldwide with Alipay+” feature available in the App, users can pay in the Chinese mainland at over 80 million merchants Tinaba with Banca Profilo announces the launch of digital payments in the Chinese mainland through the extension of its strategic partnership with Alipay+, Ant International’s global wallet gateway solution, bringing a simple, cashless and local payment experience to Italian travellers in the world’s largest digital market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122062969/en/ Matteo Arpe, President of Tinaba with Banca Profilo, announces the expanded partnership with Alipay+ in Milan, Italy Starting today, users can pay in the Chinese mainland at over 80 million merchants simply by scanning a QR code directly from the Tinaba App. This innovation is particularly significant in a country where digital payments are the everyday standard and cash is increasingly less used. The servi
Andersen Consulting indgår samarbejde med Africa International Advisors22.1.2026 22:10:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for strategi og forretningstransformation i Afrika gennem en samarbejdsaftale med Africa International Advisors (AIA), en Johannesburg-baseret virksomhed, der fokuserer på at forbedre virksomheders konkurrenceevne gennem sektorspecifik indsigt, innovation og rådgivning. AIA blev stiftet i 2002 og er et panafrikansk managementkonsulentfirma, der leverer strategibaserede rådgivningsydelser med fokus på digital transformation og ai-drevne forretningsresultater. Firmaet rådgiver kunder på tværs af sektorer, herunder energi og ressourcer, olie og gas, infrastruktur, handel og logistik, finansielle tjenesteydelser, bankvæsen og telekommunikation. AIA's strategiske perspektiv, lokale troværdighed og markedsadgang gør det muligt at udvikle og implementere løsninger, der samkører mennesker, processer og teknologi med henblik på at skabe meningsfuld forandring. "Vores mission har fra begyndelsen været at fremme udviklingen gennem en Afrika-cent
iQmetrix Announces First-Ever "Telecom Retail Summit" at MWC Barcelona 202622.1.2026 19:48:00 CET | Press release
Leading software provider challenges the industry on the growing disconnect between telecom innovation and the store experience. iQmetrix, the only global provider of Interconnected Commerce solutions for telecom retail, today announced its return to Mobile World Congress (MWC) Barcelona with the first-ever Telecom Retail Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122446809/en/ As the industry converges for MWC Barcelona 2026, iQmetrix prepares to host the first-ever Telecom Retail Summit, transforming the conversation from network intelligence to the intelligent storefront. The exclusive half-day summit designed to spark an overdue conversation: telecom sells the most advanced technology on earth, yet delivers one of the least inspiring retail experiences in modern commerce. Bringing together telecom industry leaders, futurists, and retail innovators, the Telecom Retail Summit challenges the industry to rethi
SPIE Announces the Best New Products in the Photonics Industry at Its 18th Annual Prism Awards22.1.2026 17:44:00 CET | Press release
The industry-focused awards recognized innovations in areas such as lasers, quantum tech, sensors, optical materials and components, and XR tech On 21 January, SPIE, the international society for optics and photonics, recognized the top-rated new optics and photonics products with the industry-focused Prism Awards. The gala evening, held during SPIE Photonics West, marked the Prism Awards’ 18th year of honoring companies that are bringing transformative products to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122875759/en/ Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. This year, the annual cere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom